Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294803 | 0.89 | ATM (0.41) | ATMATR | |
| SCHEMBL23294834 | 0.88 | HRH4 (0.47) | PARP1LSSDRD2DRD3HRH3 | |
| SCHEMBL23294867 | 0.88 | PARP1 (0.44) | PARP1LSSDRD2DRD3HRH3 | |
| SCHEMBL23294790 | 0.87 | CYP1A2 (0.37) | PARP1KCNH2CYP2D6HRH3EIF4E | |
| SCHEMBL23294796 | 0.87 | HRH4 (0.39) | KCNH2EIF4EMKNK1MKNK2KDR | |
| SCHEMBL23294821 | 0.87 | HRH3 (0.41) | PARP1HRH1KCNH2CYP2D6HRH3 | |
| SCHEMBL23294882 | 0.85 | CTSS (0.40) | PARP1KCNH2EIF4EMKNK1MKNK2 | |
| SCHEMBL23294879 | 0.84 | PARP1 (0.41) | PARP1LSSDRD2DRD3HRH3 | |
| SCHEMBL23294861 | 0.83 | KCNH2 (0.37) | HRH1KCNH2CYP2D6EIF4EMKNK1 | |
| SCHEMBL23339681 | 0.79 | LSS (0.48) | PARP1LSSDRD2DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | claimed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | claimed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | PARP1 126/4885LSS 3439/4885DRD2 2350/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | PARP1 126/4885LSS 3439/4885DRD2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.